Article

Predicting Personalised Therapeutic Combinations in Non-Small Cell Lung Cancer Using In Silico Modelling

2025-01-10

Abstract excerpt

The disease burden from non-small cell lung cancer (NSCLC) adenocarcinoma is substantial, with around a million new cases diagnosed globally each year, and a 5-year survival rate of less than 20%. A lack of therapeutic options personalized to individual patient genetics, and the targeted therapies that exist quickly succumbing to resistance, leads to high variation in survival. Patient stratification combined with...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4675245a-2858-53b9-b264-b041baf3a3cc
DOI: 10.1101/2025.01.07.631497

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Predicting Personalised Therapeutic Combinations in Non-Small Cell Lung Cancer Using In Silico ModellingDOI 10.1101/2025.01.07.631497Read

Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects.Semantic proximity Read

Computational platform for modelling, analysis, and prediction of anti-EGFR drug resistance for lung cancer.Semantic proximity Read

Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcomaSemantic proximity Read

Identification and molecular modelling of potential drugs targeting the genes involved in the progression of lung cancer in patients with idiopathic pulmonary fibrosisSemantic proximity Read

Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.Semantic proximity Read

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.Semantic proximity Read

Computational Advancements in Cancer Combination Therapy PredictionSemantic proximity Read

Applications of Machine Learning to Predict Cisplatin Resistance in Lung CancerSemantic proximity Read

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes.Semantic proximity Read

In vitro model for resistance in oncogene-dependent tumors at the limit of radiological detectabilitySemantic proximity Read

Anticancer Target Combinations: Network-Informed Signaling-Based Approach to DiscoverySemantic proximity Read

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.Semantic proximity Read